We performed ROC curve analysis based on low level complements (low levels of C3 and/or C4) combined with positive anti-dsDNA Ab to assess the efficiency of conventional biomarkers in predicting active lupus (SLEDAI ≥ 5) (Figure 4(a)). The gene discussed is C4A; the disease is systemic lupus erythematosus.